ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc (DRNA)

38.22
0.00
(0.00%)
Closed November 03 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
38.22
Bid
42.07
Ask
38.22
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
38.22
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

DRNA Latest News

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo...

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo...

Direxion Launches mRNA ETF (MSGR)

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK, Dec. 9, 2021 NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the...

Dicerna Shares Soar on Takeover by Novo Nordisk

By Colin Kellaher Shares of Dicerna Pharmaceuticals Inc. rose nearly 80% on Thursday after the biopharmaceutical company agreed to be acquired by collaboration partner Novo Nordisk A/S for about...

Novo Nordisk to Buy Dicerna for $38.25 a Share

By Mary de Wet Dicerna Pharmaceuticals Inc. said Thursday that Novo Nordisk AS would buy the biopharmaceutical company for $38.25 per share in cash for a total equity value of $3.3 billion. The...

Novo Nordisk to Acquire Dicerna

– Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna’s Proprietary GalXC™ Technology Platform – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today...

Dicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of Principle

By Chris Wack Dicerna Pharmaceuticals Inc. said that Eli Lilly and Co. has declared proof of principle for the first two targets in the companies' exclusive relationship in neurodegeneration...

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

– Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference...

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

– Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1 Antitrypsin –  – Enrollment in ESTRELLA Phase 2 Study of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
$ 4.98
(149.00%)
68.46M
INVZWInnoviz Technologies Ltd
$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
$ 5.87
(68.19%)
37.58M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
236.07M
TILEInterface Inc
$ 23.24
(33.03%)
2.12M
EPIXESSA Pharma Inc
$ 1.45
(-72.12%)
33.85M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
201.61M
OSTOstin Technology Group Company Ltd
$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
$ 1.23
(-36.92%)
19.96M
VCIGVCI Global Ltd
$ 0.0583
(-27.58%)
26.13M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
SQQQProShares UltraPro Short QQQ
$ 7.44
(-2.11%)
216.16M
NVDANVIDIA Corporation
$ 135.40
(1.99%)
209.27M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
INTCIntel Corporation
$ 23.20
(7.81%)
173.47M

DRNA Discussion

View Posts
ok2buy ok2buy 3 years ago
Vindicated on this one today. Being bought out. All cash offer at $38.50/share. Congrats to those who bought and held./ok2
👍️0
ok2buy ok2buy 3 years ago
US politics is driving the market lower in general. The DEMS and the REPUBS need to agree on money required to pay the existing debt and define the debt ceiling (if there is to be one). The market hates uncertainty. IMO, nothing wrong with the company. When the NAZ is moving lower by 300 - 400 points on numerous days you know there is trouble./ok2
👍️0
MomsSpaghetti MomsSpaghetti 3 years ago
That's one heck of a drop... and a lot got stopped up... Thoughts?
👍️0
XenaLives XenaLives 3 years ago
Wow - average share price >$30

Funny how they all report the same average share price.


2021-08-13 13F Rtw Investments, Lp
31.44 7,521,859 0.78 280,716 47.10
2021-08-11 13F BlackRock Inc. 31.45 5,775,534 -5.58 215,543 37.80
2021-08-13 13F Vanguard Group Inc
31.44 3,620,353 1.48 135,112 48.11
2021-08-16 13F Wellington Management Group Llp 31.45 3,299,353 -23.64 123,132 11.45
2021-08-16 13F Bain Capital Life Sciences Investors, LLC 31.44 3,080,237 0.00 114,954 45.95
2021-08-16 13F State Street Corp
31.45 2,589,062 -14.99 96,624 24.08
2021-08-16 13F Price T Rowe Associates Inc /md/ 31.45 1,982,925 17.11 74,003 70.93


https://fintel.io/so/us/drna
👍️0
XenaLives XenaLives 3 years ago
This?


Net Loss – Net loss was $40.8 million, or $0.53 per share, for the second quarter ended June 30, 2021, compared to a net loss of $31.8 million, or $0.43 per share, for the same period in 2020.


https://investors.dicerna.com/node/13526/html
👍️0
XenaLives XenaLives 3 years ago
Trying to figure out why the stock dumped after this PR:


Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Aug 05, 2021


– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants

more...



https://investors.dicerna.com/news-releases/news-release-details/dicerna-reports-positive-top-line-results-phyoxtm2-pivotal
👍️0
XenaLives XenaLives 3 years ago
Historic short interest:

Thanks for the reminder Red...

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Dicerna Pharmaceuticals, Inc. - Common Stock
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

09/15/2021 4,126,869 0.11 914,655 4.51
08/31/2021 4,122,137 (19.29) 1,163,697 3.54
08/13/2021 5,107,461 9.86 1,938,271 2.64
07/30/2021 4,649,214 (2.20) 630,504 7.37
07/15/2021 4,753,763 19.05 742,954 6.40
06/30/2021 3,993,134 (19.41) 794,900 5.02
06/15/2021 4,954,651 (2.49) 703,160 7.05
05/28/2021 5,080,919 (8.42) 652,085 7.79
05/14/2021 5,547,789 (2.95) 669,937 8.28
04/30/2021 5,716,157 2.64 604,337 9.46
04/15/2021 5,569,312 4.58 510,702 10.91
03/31/2021 5,325,524 3.22 839,178 6.35
03/15/2021 5,159,496 3.86 908,857 5.68
02/26/2021 4,967,839 7.46 657,667 7.55
02/12/2021 4,622,947 (4.76) 631,608 7.32
01/29/2021 4,854,056 (0.06) 814,938 5.96
01/15/2021 4,856,795 (6.76) 685,284 7.09
12/31/2020 5,208,863 (11.94) 620,536 8.39
12/15/2020 5,915,239 1.85 692,346 8.54
11/30/2020 5,807,929 0.68 382,409 15.19
11/13/2020 5,768,562 (0.36) 564,424 10.22
10/30/2020 5,789,376 24.06 602,784 9.60
10/15/2020 4,666,501 (1.74) 428,490 10.89
09/30/2020 4,749,326 22.31 525,176 9.04


👍️0
XenaLives XenaLives 3 years ago
Institutional Shares 69,547,052 - 89.47% (ex 13D/G)

Institutional Ownership and Shareholders
Dicerna Pharmaceuticals Inc (US:DRNA) has 429 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 69,547,052 shares. Largest shareholders include Rtw Investments, Lp, BlackRock Inc., Vanguard Group Inc, Wellington Management Group Llp, Bain Capital Life Sciences Investors, LLC, State Street Corp, Price T Rowe Associates Inc /md/, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Aquilo Capital Management, LLC, and IWM - iShares Russell 2000 ETF.

Dicerna Pharmaceuticals Inc (US:DRNA) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

https://fintel.io/so/us/drna

👍️0
ok2buy ok2buy 3 years ago
Added again last week on this one. Buy and hold, should move back up. Best of luck to the longs./ok2
👍️0
ok2buy ok2buy 3 years ago
Bought today with the roll back. Institutions own 85 % of the stock. Will hold if necessary, money in the bank./ok2
👍️0
PennyStock Alert PennyStock Alert 5 years ago
will be interesting after the 1/10 with 6.2 mil shares o/s instead of the current 62 mil
👍️0
wiltonio wiltonio 8 years ago
Domain Partners VIII, L.P. has filed a new activist 13D, reporting 14.9% ownership in $DRNA - https://fintel.io/so/us/drna
👍️0
ValueInvestor15 ValueInvestor15 8 years ago
Dicerna Pharma $DRNA has little Margin of Safety for Value Investors before earnings Wednesday:

Fair Value Source
👍️0
Warchest Warchest 8 years ago
+.25 !!
👍️0
Warchest Warchest 8 years ago
chart looking good !!!
👍️0
INTL INTL 8 years ago
Possible breakout
👍️0
ClayTrader ClayTrader 8 years ago
* * $DRNA Video Chart 09-29-16 * *

Link to Video - click here to watch the technical chart video
👍️0
stocktrademan stocktrademan 10 years ago
$DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA

bullish
quick trade

$DRNA recent news/filings

## source: finance.yahoo.com

Wed, 17 Dec 2014 23:58:56 GMT ~ Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced ...

read full: http://www.noodls.com/view/03BF21AF94C12E65B84F7443AA9F6916484BF35C
*********************************************************

Wed, 17 Dec 2014 23:36:00 GMT ~ Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore T.

read full: http://finance.yahoo.com/news/dicerna-announces-appointment-theodore-t-233600639.html
*********************************************************

Mon, 15 Dec 2014 12:12:30 GMT ~ Dicerna R&D Update Webcast Reminder

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, ...

read full: http://www.noodls.com/view/B6D67345529B90360B6D6BAD66985311ACD0E760
*********************************************************

Mon, 15 Dec 2014 12:00:00 GMT ~ Dicerna R&D Update Webcast Reminder

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, announces webcast and conference call information for its previously announced R&D Update webcast later today, December 15, 2014, at 4:30 p.m.

read full: http://finance.yahoo.com/news/dicerna-r-d-webcast-reminder-120000794.html
*********************************************************

Tue, 25 Nov 2014 14:30:15 GMT ~ Dicerna to Present at the 2014 Deutsche Bank BioFEST

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, ...

read full: http://www.noodls.com/view/F9E1C4DA99D749941B37AA7031DE970335309AA9
*********************************************************


$DRNA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$DRNA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DRNA/company-info
Ticker: $DRNA
OTC Market Place: Not Available
CIK code: not found
Company name: Dicerna Pharmaceuticals, Inc.
Incorporated In:


$DRNA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$DRNA extra dd links

Company name: Dicerna Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DRNA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DRNA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DRNA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/news - http://finance.yahoo.com/q/h?s=DRNA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DRNA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DRNA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DRNA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dicerna+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dicerna+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dicerna+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DRNA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DRNA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DRNA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DRNA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DRNA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DRNA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DRNA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DRNA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DRNA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DRNA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DRNA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DRNA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DRNA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DRNA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DRNA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DRNA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DRNA



$DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA
👍️0